Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT01859988 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

380

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: Dupilumab
DRUG: Placebo

Sponsor

Regeneron Pharmaceuticals

Collaborators

[object Object]